Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of JT001 (Deuremidevir) in Hepatic Impairment
NCT06093230Phase 1Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoints: Maximum Plasma Concentration of 116-N1 at 72 hours, Area Under the Curve to Last Measurable Concentration of 116-N1 at 72 hours and 11 more. Started Jul 2023; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06093230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093230.